RankAlpha logo
Back to Rankings

LPCN

LipocineA
Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-06-02
View Chart
Current thesis
The upside case is that April's failed primary readout still leaves enough subgroup signal, safety differentiation, and regulatory optionality for LPCN 1154 to remain monetizable via a validation study, partnership, or strategic transaction, while TLANDO-related licensing and royalty streams provide some non-zero asset backing.
Posture
Constructive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Any regulatory path based on subgroup findings is uncertain and may require additional study work.
Momentum
100
Value
42
Sentiment
44
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $2.10 · Bull $3.40 · Bear $1.20
Data freshness
Prices
As of 2026-06-02
Fundamentals
As of 2026-05-29 • Vendor: Data Vendor v1
Scores
As of 2026-06-02 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-21 • Model: RankAlpha Sentiment Codex
Investment thesis
As of 2026-06-02
Supporting evidence
What
Grade A · Constructive
Confidence Medium · Net Neutral
Target $10.88
Why
Momentum100 · Δ7d -
Value42 · Δ7d +0.1
Sentiment44 · Δ7d -
So what
Strength-led posture (Net Neutral). Favor watchlist adds and disciplined entries.
Lead driver: Momentum · See technicals
Momentum
100
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
42
32% active weight
Current posture
7d trendFlat
Δ7d
+0.1
Δ21d
+0.2
Sentiment
44
33% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade

Composite grade A. Momentum 99.5 / Value 41.9 / Sentiment 44.5

Fundamentals (TTM)
As of 2026-05-29
Market Cap
$18.55M
Beta
0.99
Shares Out
5.55M
P/E (TTM)
-
P/S (TTM)
9.38
P/FCF (TTM) · Derived
-3.54
Rev YoY
+595.4%
EPS YoY
-41.9%
Gross Margin
-
Op Margin
-146.0%
Net Debt
-$21.63M
Current Ratio
8.25
As of 2026-06-02 • Updated nightlySource: Internal modelMethodology